epysqli
(Eculizumab-aagh)Samsung Bioepis Co., Ltd.
Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. Limitations apply for STEC-HUS.